Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-633
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-633 is an oral agent that was under development by Merck for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The drug was investigated as a potential therapy to address respiratory symptoms and disease progression in COPD, but there is no evidence it reached advanced clinical development or approval. Its precise mechanism of action has not been publicly disclosed.
- Other names
- setileuton
02
Targets
P2XR (P2X receptor family)P2X3 (P2X purinoceptor 3)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on MK-633.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-633.